| 國立成功大學 |
2024-09 |
Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)-SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
|
Garcia, Moreno;V;Oh;D-Y;Ryu;M, H.;Calvo;E;Garralda;E;Chung;W-P;Bai;L-Y;Laimito, Rojas;K, I.;Yildirim;O;Masciari;S;Mi;G;Wang;L;Kanlikilicer;P;Buday;B;Rharbaoui;F;Abbadessa;G;Dumbrava;E, E. E. |
| 國立成功大學 |
2024-09 |
Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100
|
Grivas;P;Park;S, H.;Voog;E;Su;W-P;Demey;W;Fong;P, C.;Garcia;J, A.;Jacob;N;Gerhold-Ay;A;Tyroller;K;Hoffman;J;Bellmunt;J;Powles;T, B. |
| 國立成功大學 |
2024-09 |
Initial results from a first-in-human study of AZD5335, a folate receptor a (FRa)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
|
Shapira-Frommer;R;Sudo;K;Harano;K;Mileshkin;L;Perets;R;Song;M;Cohen;J;Huang;Y-F;Ambrose;H;Brier;T;Dosani;A;Fraenkel;P, G.;Kmieciak;A;Mitchell;P;Myers;C;Wang;J;Odegbami;R, I.;Sykes;A;Turner;S;Meric-Bernstam;F |
| 國立成功大學 |
2024-09 |
Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study
|
Toullec;C;Seo;S;Robinson;A, G.;Chou;H-H;Salman;P;Ghiringhelli;F;Ozyilkan;O;Rojas;C, I.;Sendur;M, A. N.;Tourneau, Le;C;Yen;C, J.;Aksoy;S;Ochsenreither;S;Ruiz;Yanez, E. P.;Rha;S, Y.;Shapira-Frommer;R;Liu;Q;Plessis, Du;M;Keenan;T;Hsu;C-H |
| 國立成功大學 |
2024-09 |
Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005
|
Seo;S;Calderon;B;Chou;H-H;Hsu;C-H;Salman;P;Ghiringhelli;F;Ozyilkan;O;Rojas;C, I.;Sendur;M, A. N.;Tourneau, Le;C;Yen;C, J.;Shapira-Frommer;R;Rha;S, Y.;Zhang;Y;Chen;C;Pena;C, E.;Keenan;T;Chen;Y;Dettman;E;Robinson;A, G. |
| 國立成功大學 |
2024-09 |
Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)-SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
|
Garcia, Moreno;V;Oh;D-Y;Ryu;M, H.;Calvo;E;Garralda;E;Chung;W-P;Bai;L-Y;Laimito, Rojas;K, I.;Yildirim;O;Masciari;S;Mi;G;Wang;L;Kanlikilicer;P;Buday;B;Rharbaoui;F;Abbadessa;G;Dumbrava;E, E. E. |
| 國立成功大學 |
2024-09 |
Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study
|
Chen;X-P;Yen;C, J.;Huang;P;Lin;C-C;Wang;J;Li;D;Li;Y;Gu;S;Li;G;Du;X;Sun;M;Dai;C;Qian;J;Liu;C;Liu;J;Zhuang;Z;Zhang;F;Kong;G;Cheng;Q;Cheng;A-L |
| 國立成功大學 |
2024-09 |
Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study
|
Toullec;C;Seo;S;Robinson;A, G.;Chou;H-H;Salman;P;Ghiringhelli;F;Ozyilkan;O;Rojas;C, I.;Sendur;M, A. N.;Tourneau, Le;C;Yen;C, J.;Aksoy;S;Ochsenreither;S;Ruiz;Yanez, E. P.;Rha;S, Y.;Shapira-Frommer;R;Liu;Q;Plessis, Du;M;Keenan;T;Hsu;C-H |
| 國立成功大學 |
2024-09 |
Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study
|
Chen;X-P;Yen;C, J.;Huang;P;Lin;C-C;Wang;J;Li;D;Li;Y;Gu;S;Li;G;Du;X;Sun;M;Dai;C;Qian;J;Liu;C;Liu;J;Zhuang;Z;Zhang;F;Kong;G;Cheng;Q;Cheng;A-L |
| 國立成功大學 |
2024-09 |
Does the primary location and metastatic timing of colorectal cancer influence the survival of patients with brain metastasis? A meta-analysis
|
Song;J;Yim;C;Tsai;T-C;Memon;R;Chi;K-Y;Gong;C;Lin;B-W;Lin;H-M;Chang;Y |
